XGenomes

Cambridge, Massachusetts, United States

BiotechGenetic DisordersDiagnostics

At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix concurrently. The sequence we produce will be complete, encompassing: structural as well as single nucleotide variants; long-range haplotype phase; the repetitive dark matter" of the genome. The cost of goods (consumables) of sequencing will be <$10 which will allow us to price our product at a level that will help grow the market while still achieving >90% margin. We will start by offering access as a service to high value customers which be followed by a razor and blade model of selling instruments and consumables.